Apyx Medical Posts Encouraging Data From Renuvion Device In Sagging Skin

• Apyx Medical Corp (NASDAQ: APYX) announced results from Phase 2 of its Investigational Device Exemption (IDE) study of the Renuvion device to improve the appearance of lax skin in the neck and submental region.

• The 65-subject study showed that the primary effectiveness endpoint of the study was met, with 82.5% of subjects demonstrating improvement in the appearance of lax skin at six months post-procedure.

• Related: Why Apyx Medical Shares Are Trading Higher Today?

• 96.9% of subjects experienced no to moderate pain during the first seven days following the procedure.

• Additional effectiveness endpoints in the study also demonstrated success, with 85.5% of subjects rating themselves as improved and 87.1% of subjects rated improved by the study investigators at the 6-month follow-up visit.

• No serious adverse events were reported in the study related to the Renuvion device or the study procedure.

• Price Action: APYX shares closed 5.16% higher at $6.93 on Friday.

See more from Benzinga

• SOBI-Sanofi Partnered Hemophilia Therapy Shows Superior Bleed Protection Than Prior Prophylaxis

• Patient Death Prompts MacroGenics To Close Mid-Stage Head & Cancer Study

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.